Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | D3S-001 |
Synonyms | |
Therapy Description |
D3S-001 inhibits KRAS G12C, potentially resulting in decreased tumor cell proliferation and tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e15102). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
D3S-001 | D3S001|D3S 001 | KRAS G12C inhibitor 34 | D3S-001 inhibits KRAS G12C, potentially resulting in decreased tumor cell proliferation and tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e15102). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05410145 | Phase I | D3S-001 | A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Recruiting | USA | AUS | 3 |